Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous mesothelin-specific CAR-T cells expressing anti-PD-1/CTLA-4 antibodies

A preparation of autologous, engineered T lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CTLA-4/PD-1 antibodies-expressing meso-CAR-T cells
autologous anti-CTLA-4/PD-1 antibodies-expressing mesothelin-targeted CAR-T cells
autologous anti-MG7 CAR-T cells
autologous anti-MG7-CAR T lymphocytes
autologous CTLA-4 and PD-1 antibodies expressing mesothelin-CAR-T cells
autologous CTLA4/PD-1-targeting antibodies-expressing mesothelin-CAR-T cells
autologous MG7-CART
autologous MG7-CART cells
MG7-targeted chimeric antigen receptor T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search